Showing results (171-180 of 437) with videos related to

Sort By:
Pageof 44
Blood|March 29, 2007
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cellsShaozhong Dong, Sumin Kang, Ting-Lei Gu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell productsSagar Lonial, Michelle Hicks, Hilary Rosenthal, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Leukemia & Lymphoma|October 31, 2006
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphomaSagar Lonial, Martha Arellano, Donald Hutcherson, et al.
The Journal of Clinical Investigation|August 1, 2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancyM Hope Robinson, Nancy Y Villa, David L Jaye, et al.
The Oncologist|January 13, 2006
A practical update on the use of bortezomib in the management of multiple myelomaJesús San Miguel, Joan Bladé, Mario Boccadoro, et al.
Cancer|April 21, 2012
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemiaMartha Arellano, Suchita Pakkala, Amelia Langston, et al.
Cancer Medicine|April 28, 2016
Lack of health maintenance examinations and risk in myeloma patientsJoseph D Tariman, Charise Gleason, Beth Faiman, et al.
Cancer|May 20, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3Ajay K Nooka, Christopher Strouse, Sarah M Larson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2003
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effectsCynthia R Giver, Richard O Montes, Stephen Mittelstaedt, et al.
Pageof 44